BioCentury
ARTICLE | Clinical News

Early data for Enyo's HBV, NASH candidate tee up Phase II

November 9, 2018 6:16 PM UTC

Enyo Pharma S.A. (Lyon, France) said once-daily oral EYP001 for four weeks was well tolerated with no off-target effects or serious adverse events reported in a Phase Ib trial to treat chronic HBV infection. The company plans to start Phase II testing of EYP001 this quarter to treat non-alcoholic steatohepatitis (NASH) and in 1Q19 to treat chronic HBV infection.

The double-blind, international trial enrolled 73 patients with chronic HBV infection to receive placebo, EYP001 alone, EYP001 plus peginterferon α2a, or the active control entecavir...

BCIQ Company Profiles

Enyo Pharma S.A.